Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06636552 |
Title | An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L (EUMELEIA) |
Acronym | EUMELEIA |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Hellenic Society of Hematology |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | GRC |